Effect of L-carnitine on COVID-19

Comparison of the complementary effect of L-carnitine and placebo on the clinical outcomes of patients with COVID-19 (2019-nCov) admitted to the intensive care unit

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20151108024938N3

Enrollment

Registered

2023-08-21

Start date

2020-04-20

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Acute respiratory infection caused by coronavirus. Condition 2: Acute respiratory infection caused by coronavirus. COVID-19, virus not identified COVID-19, virus identified

Interventions

Intervention 1: Intervention group: Receiver of 3000 mg of L-carnitine daily for 7 days by gavage from Kasra-zist takhmir bonyan company. Intervention 2: Control group: Receiving 10 cc pasteurized dri

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: All patients COVID-19, admitted to intensive care unit Age 18-65 years old Satisfaction to participate in the study

Exclusion criteria

Exclusion criteria: Covid-19 with mold diarrhea History of L-carnitine allergy Use of anticonvulsant drugs Hemodialysis

Design outcomes

Primary

Measure	Time frame
Ventilator dependence. Timepoint: Before and 7 days after intervention. Method of measurement: Using ABG and the opinion of an anesthesiologist.;C-reactive protein (CRP). Timepoint: Before and 7 days after intervention. Method of measurement: Quantitative method, by ELISA method.	—

Secondary

Measure	Time frame
Mortality within the intensive care unit. Timepoint: Before intervention and 7 days after intervention. Method of measurement: Observe the occurrence.;The ratio of neutrophils to lymphocytes. Timepoint: Before intervention and 7 days after intervention. Method of measurement: Using a complete blood test.;Blood levels of lactate dehydrogenase. Timepoint: Before intervention and 7 days after intervention. Method of measurement: Enzymatic method.;The incidence of sepsis. Timepoint: Before intervention and 7 days after intervention. Method of measurement: Based on the diagnosis of the treating physician and SIRS criteria.;The incidence of respiratory distress. Timepoint: Before intervention and 7 days after intervention. Method of measurement: Based on the diagnosis of the treating physician and SIRS criteria.	—

Measure

Time frame

Mortality within the intensive care unit. Timepoint: Before intervention and 7 days after intervention. Method of measurement: Observe the occurrence.;The ratio of neutrophils to lymphocytes. Timepoint: Before intervention and 7 days after intervention. Method of measurement: Using a complete blood test.;Blood levels of lactate dehydrogenase. Timepoint: Before intervention and 7 days after intervention. Method of measurement: Enzymatic method.;The incidence of sepsis. Timepoint: Before intervention and 7 days after intervention. Method of measurement: Based on the diagnosis of the treating physician and SIRS criteria.;The incidence of respiratory distress. Timepoint: Before intervention and 7 days after intervention. Method of measurement: Based on the diagnosis of the treating physician and SIRS criteria.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed Mostafa Arabi

Mashhad University of Medical Sciences

arabim941@mums.ac.ir+98 51 3882 8574

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026